Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial | Psychiatry and Behavioral Health | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.185.54. Please contact the publisher to request reinstatement.
1.
Saykin  AJGur  RCGur  REMozley  PDMozley  LHResnick  SMKester  DBStafiniak  P Neuropsychological function in schizophrenia: selective impairment in memory and learning.  Arch Gen Psychiatry 1991;48618- 624PubMedGoogle ScholarCrossref
2.
Braff  DLHeaton  RKuck  JCullum  MMoranville  JGrant  IZisook  S The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results.  Arch Gen Psychiatry 1991;48891- 898PubMedGoogle ScholarCrossref
3.
Brickman  AMPaul  RHCohen  RAWilliams  LMMacGregor  KLJefferson  ALTate  DFGunstad  JGordon  E Category and letter verbal fluency across the adult lifespan: relationship to EEG theta power.  Arch Clin Neuropsychol 2005;20561- 573PubMedGoogle ScholarCrossref
4.
Saykin  AJShtasel  DLGur  REKester  DBMozley  LHStafiniak  PGur  RC Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.  Arch Gen Psychiatry 1994;51124- 131PubMedGoogle ScholarCrossref
5.
Davidson  MReichenberg  ARabinowitz  JWeiser  MKaplan  ZMark  M Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents.  Am J Psychiatry 1999;1561328- 1335PubMedGoogle Scholar
6.
Reichenberg  AWeiser  MRapp  MARabinowitz  JCaspi  ASchmeidler  JKnobler  HYLubin  GNahon  DHarvey  PDDavidson  M Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia.  Arch Gen Psychiatry 2005;621297- 1304PubMedGoogle ScholarCrossref
7.
Fuller  RNopoulos  PArndt  SO’Leary  DHo  BCAndreasen  NC Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance.  Am J Psychiatry 2002;1591183- 1189PubMedGoogle ScholarCrossref
8.
Heinrichs  RWZakzanis  KK Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.  Neuropsychology 1998;12426- 445PubMedGoogle ScholarCrossref
9.
Bilder  RMGoldman  RSRobinson  DReiter  GBell  LBates  JAPappadopulos  EWillson  DFAlvir  JMWoerner  MGGeisler  SKane  JMLieberman  JA Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.  Am J Psychiatry 2000;157549- 559PubMedGoogle ScholarCrossref
10.
Keefe  RSESeidman  LJChristensen  BKHamer  RMSharma  TSitskoorn  MMLewine  RRJYurgelun-Todd  DARuben  CGTohen  MTollefson  GDSanger  TMLieberman  JA Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.  Am J Psychiatry 2004;161985- 995PubMedGoogle ScholarCrossref
11.
Gold  JMQueern  CIannone  VNBuchanan  RW Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: sensitivity, reliability, and validity.  Am J Psychiatry 1999;1561944- 1950PubMedGoogle Scholar
12.
Green  MF What are the functional consequences of neurocognitive deficits in schizophrenia?  Am J Psychiatry 1996;153321- 330PubMedGoogle Scholar
13.
Harvey  PDHowanitz  EParrella  MWhite  LDavidson  MMohs  RCHoblyn  JDavis  KL Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.  Am J Psychiatry 1998;1551080- 1086PubMedGoogle Scholar
14.
Hyman  SEFenton  WS Medicine: what are the right targets for psychopharmacology?  Science 2003;299350- 351PubMedGoogle ScholarCrossref
15.
Keefe  RSESeidman  LJChristensen  BKHamer  RMSharma  TSitskoorn  MMRock  SLWoolson  STohen  MTollefson  GDSanger  TMLieberman  JA Two-year neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.  Biol Psychiatry 2006;5997- 105PubMedGoogle ScholarCrossref
16.
Kern  RSGreen  MFMarshall  BD  JrWirshing  WCWirshing  DMcGurk  SRMarder  SRMintz  J Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.  Biol Psychiatry 1998;44726- 732PubMedGoogle ScholarCrossref
17.
Kivircik Akdede  BBAlptekin  KKitis  AArkar  HAkvardar  Y Effects of quetiapine on cognitive functions in schizophrenia.  Prog Neuropsychopharmacol Biol Psychiatry 2005;29233- 238PubMedGoogle ScholarCrossref
18.
Wagner  MQuednow  BBWestheide  JSchlaepfer  TEMaier  WKuhn  K Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs. amisulpride.  Neuropsychopharmacology 2005;30381- 390PubMedGoogle ScholarCrossref
19.
McGurk  SRCarter  CGoldman  RGreen  MFMarder  SRXie  HSchooler  NRKane  JM The effects of clozapine and risperidone on spatial working memory in schizophrenia.  Am J Psychiatry 2005;1621013- 1016PubMedGoogle ScholarCrossref
20.
Harvey  PDMeltzer  HSimpson  GMPotkin  SGLoebel  ASiu  CRomano  SJ Improvements in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.  Schizophr Res 2004;66101- 113PubMedGoogle ScholarCrossref
21.
McGurk  SRLee  MAJayathilake  KMeltzer  H Cognitive effects of olanzapine treatment in schizophrenia.  MedGenMed 2004;627PubMedGoogle Scholar
22.
Harvey  PDGreen  MFMcGurk  SRMeltzer  HY Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.  Psychopharmacology (Berl) 2003;169404- 411PubMedGoogle ScholarCrossref
23.
Harvey  PDNapolitano  JAMao  LGharabawi  G Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.  Int J Geriatr Psychiatry 2003;18820- 829PubMedGoogle ScholarCrossref
24.
Harvey  PDSiu  CORomano  S Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.  Psychopharmacology (Berl) 2004;172324- 332PubMedGoogle ScholarCrossref
25.
Stip  ERemington  GJDursun  SMReiss  JPRotstein  EMacEwan  GWChokka  PRJones  BDickson  RAA Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine.  J Clin Psychopharmacol 2003;23400- 404PubMedGoogle ScholarCrossref
26.
Sharma  THughes  CSoni  WKumari  V Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.  Psychopharmacology (Berl) 2003;169398- 403PubMedGoogle ScholarCrossref
27.
Velligan  DIPrihoda  TJSui  DRitch  JLMaples  NMiller  AL The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.  J Clin Psychiatry 2003;64524- 531PubMedGoogle ScholarCrossref
28.
Bilder  RMGoldman  RSVolavka  JCzobor  PHoptman  MSheitman  BLindenmayer  JPCitrome  LMcEvoy  JKunz  MChakos  MCooper  TBHorowitz  TLLieberman  JA Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.  Am J Psychiatry 2002;1591018- 1028PubMedGoogle ScholarCrossref
29.
Good  KPKiss  IBuiteman  CWoodley  HRui  QWhitehorn  DKopala  L Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis.  Br J Psychiatry Suppl 2002;43s45- s49PubMedGoogle ScholarCrossref
30.
Vaiva  GThomas  PLlorca  PMDupont  SCottencin  ODevos  PMazas  ORascle  CSteinling  MGoudemand  M SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome.  Psychiatry Res 2002;11537- 48PubMedGoogle ScholarCrossref
31.
Velligan  DINewcomer  JPultz  JCsernansky  JHoff  ALMahurin  RMiller  AL Does cognitive function improve with quetiapine in comparison to haloperidol?  Schizophr Res 2002;53239- 248PubMedGoogle ScholarCrossref
32.
Chua  LChong  SAPang  ENg  VPYChan  YH The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore.  Singapore Med J 2001;42243- 246PubMedGoogle Scholar
33.
Fleming  KThyrum  PYeh  CVargo  DLPotkin  SG Cognitive improvement in psychotic subjects treated with “Seroquel” (quetiapine fumarate): an exploratory study.  J Clin Psychopharmacol 2001;21527- 529PubMedGoogle ScholarCrossref
34.
Potkin  SGFleming  KJin  YGulasekaram  B Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics.  J Clin Psychopharmacol 2001;21479- 483PubMedGoogle ScholarCrossref
35.
Purdon  SELabelle  ABoulay  L Neuropsychological change in schizophrenia after 6 weeks of clozapine.  Schizophr Res 2001;4857- 67PubMedGoogle ScholarCrossref
36.
Purdon  SEMalla  ALabelle  ALit  W Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.  J Psychiatry Neurosci 2001;26137- 149PubMedGoogle Scholar
37.
Smith  RCInfante  MSingh  AKhandat  A The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.  Int J Neuropsychopharmacol 2001;4239- 250PubMedGoogle ScholarCrossref
38.
Purdon  SEJones  BDWStip  ELabelle  AAddington  DDavid  SBreier  ATollefson  GD Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, and haloperidol.  Arch Gen Psychiatry 2000;57249- 258PubMedGoogle ScholarCrossref
39.
Lee  MAJayathilake  KMeltzer  HY A comparison of the effect of clozapine with typical neuroleptics on cognitive function on neuroleptic responsive schizophrenia.  Schizophr Res 1999;371- 11PubMedGoogle ScholarCrossref
40.
Galletly  CAClark  CRMcFarlane  ACWeber  DL Effects of clozapine for non-treatment-resistant patients with schizophrenia.  Psychiatr Serv 1999;50101- 103PubMedGoogle Scholar
41.
Kern  RSGreen  MFBarringer  MD  JrWirshing  WCWirshing  DMcGurk  SRMarder  SRMintz  J Risperidone versus haloperidol on secondary memory: can newer medications air learning?  Schizophr Bull 1999;25223- 232PubMedGoogle ScholarCrossref
42.
Manschreck  TCRedmond  DACandela  SFMaher  BA Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia.  J Neuropsychiatry Clin Neurosci 1999;11481- 489PubMedGoogle Scholar
43.
Meltzer  HYMcGurk  SR The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.  Schizophr Bull 1999;25233- 255PubMedGoogle ScholarCrossref
44.
Rossi  AMancini  FStratta  PMattei  PGismondi  RPozzi  FCasacchia  M Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.  Acta Psychiatr Scand 1997;9540- 43PubMedGoogle ScholarCrossref
45.
Serper  MRChou  JCY Novel neuroleptics improve attentional functioning in schizophrenia patients: ziprasidone and aripiprazole.  CNS Spectr 1997;256- 59Google Scholar
46.
Fujii  DEAhmed  IJokumsen  MCompton  JM The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients.  J Neuropsychiatry Clin Neurosci 1997;9240- 245PubMedGoogle Scholar
47.
Hoff  ALFaustman  WOWieneke  MEspinoza  SCosta  MWolkowitz  OCsernansky  JC The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.  Neuropsychopharmacology 1996;15361- 369PubMedGoogle ScholarCrossref
48.
Lee  MAThompson  PMeltzer  H Effects of clozapine on cognitive function in schizophrenia.  J Clin Psychiatry 1994;5582- 87PubMedGoogle Scholar
49.
Buchanan  RWHolstein  CBreier  A The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.  Biol Psychiatry 1994;36717- 725PubMedGoogle ScholarCrossref
50.
Hagger  CBuckley  PKenny  JTFreidman  LUbogy  DMeltzer  HY Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.  Biol Psychiatry 1993;34702- 712PubMedGoogle ScholarCrossref
51.
Keefe  RSSilva  SGPerkins  DOLieberman  JA The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.  Schizophr Bull 1999;25201- 222PubMedGoogle ScholarCrossref
52.
Harvey  PDKeefe  RS Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.  Am J Psychiatry 2001;158176- 184PubMedGoogle ScholarCrossref
53.
Woodward  NDPurdon  SEMeltzer  HYZald  DH A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.  Int J Neuropsychopharmacol 2005;8457- 472PubMedGoogle ScholarCrossref
54.
Carpenter  WTGold  JM Another view of therapy for cognition in schizophrenia.  Biol Psychiatry 2002;51969- 971PubMedGoogle ScholarCrossref
55.
Heres  SDavis  JMaino  KJetzinger  EKissling  WLeucht  S Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.  Am J Psychiatry 2006;163185- 194PubMedGoogle ScholarCrossref
56.
Robinson  DGWoerner  MGAlvir  JMBilder  RMHinrichsen  GALieberman  JA Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.  Schizophr Res 2002;57209- 219PubMedGoogle ScholarCrossref
57.
Stroup  TSMcEvoy  JPSwartz  MSByerly  MJGlick  IDCanive  JMMcGee  MFSimpson  GMStevens  MCLieberman  JA The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.  Schizophr Bull 2003;2915- 31PubMedGoogle ScholarCrossref
58.
Keefe  RSMohs  RCBilder  RMHarvey  PDGreen  MFMeltzer  HYGold  JMSano  M Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.  Schizophr Bull 2003;2945- 55PubMedGoogle ScholarCrossref
59.
Keefe  RSEBilder  RMHarvey  PDDavis  SMPalmer  BWGold  JMMeltzer  HYGreen  MFMiller  DDCanive  JMAdler  LWManschreck  TCSwartz  MRosenheck  RPerkins  DOWalker  TMStroup  TSMcEvoy  JPLieberman  JA Baseline neurocognitive deficits in the CATIE Schizophrenia Trial.  Neuropsychopharmacology 2006;312033- 2046PubMedGoogle ScholarCrossref
60.
S wartz  MSPerkins  DOStroup  TSMcEvoy  JPNieri  JMHaak  DC Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.  Schizophr Bull 2003;2933- 43PubMedGoogle ScholarCrossref
61.
Davis  SMKoch  GGDavis  CELaVange  LM Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies.  Schizophr Bull 2003;2973- 80PubMedGoogle ScholarCrossref
62.
Rosenheck  RDoyle  JLeslie  DFontana  A Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs.  Schizophr Bull 2003;2981- 93PubMedGoogle ScholarCrossref
63.
Lieberman  JAStroup  TSMcEvoy  JPSwartz  MSRosenheck  RAPerkins  DOKeefe  RSDavis  SMDavis  CELebowitz  BDSevere  JHsiao  JKClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med 2005;3531209- 1223PubMedGoogle ScholarCrossref
64.
Stroup  TSLieberman  JAMcEvoy  JPSwartz  MSDavis  SMRosenheck  RAPerkins  DOKeefe  RSEDavis  CESevere  JHsiao  JKthe CATIE Investigators, Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuing a previous atypical antipsychotic.  Am J Psychiatry 2006;163611- 622PubMedGoogle ScholarCrossref
65.
McEvoy  JPLieberman  JAStroup  TSDavis  SMRosenheck  RASwartz  MSPerkins  DOKeefe  RSEDavis  CESevere  JHsiao  JKCATIE Investigators, Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.  Am J Psychiatry 2006;163600- 610PubMedGoogle ScholarCrossref
66.
Kay  SRFiszbein  AOpler  LA The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia.  Schizophr Bull 1987;13261- 276PubMedGoogle ScholarCrossref
67.
Jastak  SWilkinson  GS Wide Range Achievement Test–Revised 3.  Wilmington, Del Jastak Associates1993;
68.
Hochberg  Y A sharper Bonferroni procedure for multiple tests of significance.  Biometrika 1988;75800- 803Google ScholarCrossref
69.
Guy  W ECDEU Assessment Manual.  Rockville, Md USDHEW1976;
70.
Tracy  KAdler  LARotrosen  JEdson  RLavori  P Interrater reliability issues in multicenter trials, part I: theoretical concepts and operational procedures in Department of Veterans Administration Cooperative Study #394.  Psychopharmacol Bull 1997;3353- 57PubMedGoogle Scholar
71.
 IMS Health. Atypical antipsychotics—generating evidence to inform policy and practice. http://research.imshealth.com/research/research_schizophrenia.htm. Accessed August 26, 2005 
72.
Faries  DAscher-Svanum  HZhu  BCorrell  CKane  J Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.  BMC Psychiatry 2005;526PubMedGoogle ScholarCrossref
73.
Benton  ALHamscher  K Multilingual Aphasia Examination Manual. Revised.  Iowa City University of Iowa1978;
74.
Wechsler  D Wechsler Intelligence Scale for Children. 3rd ed Orlando, Fla Harcourt Publishers1991;
75.
Gold  JMCarpenter  CRandolph  CGoldberg  TEWeinberger  DR Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.  Arch Gen Psychiatry 1997;54159- 165PubMedGoogle ScholarCrossref
76.
Brandt  JBenedict  R Hopkins Verbal Learning Test.  Lutz, Fla Psychological Assessment Resources1991;
77.
Wechsler  D Wechsler Adult Intelligence Scale. Revised Edition San Antonio, Tex Psychological Corp1974;
78.
Lafayette Instrument Company, Grooved Pegboard Instruction Manual, Model 32025.  Lafayette, Ind Lafayette Instrument Co1989;
79.
Cornblatt  BAKeilp  JG Impaired attention, genetics, and the pathophysiology of schizophrenia.  Schizophr Bull 1994;2031- 46PubMedGoogle ScholarCrossref
80.
Lyons-Warren  ALillie  RHershey  T Short and long-term spatial delayed response performance across the lifespan.  Dev Neuropsychol 2004;26661- 678PubMedGoogle ScholarCrossref
81.
Kongs  SKThompson  LLIverson  GLHeaton  RK Wisconsin Card Sorting Test—64 Card Version Professional Manual.  Odessa, Fla Psychological Assessment Resources, Inc2000;
82.
Rosenheck  RA Open forum: effectiveness versus efficacy of second-generation antipsychotics. haloperidol without anticholinergics as a comparator.  Psychiatr Serv 2005;5685- 92PubMedGoogle ScholarCrossref
83.
Høyberg  OJFensbo  CRemvig  JLingjaerde  OSloth-Nielsen  MSalvesen  I Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.  Acta Psychiatr Scand 1993;88395- 402PubMedGoogle ScholarCrossref
84.
Fruensgaard  KWollenberg  JHansen  KMFensbo  CSihm  F Loxapine versus perphenazine in psychotic patients: a double-blind, randomized, multicentre trial.  Curr Med Res Opin 1978;5601- 607PubMedGoogle ScholarCrossref
85.
Van Putten  TMarder  SRWirshing  WCAravagiri  MChabert  N Neuroleptic plasma levels.  Schizophr Bull 1991;17197- 216PubMedGoogle ScholarCrossref
86.
Sweet  RAPollock  BGMulsant  BHRosen  JSorisio  DKirshner  MHenteleff  RDeMichele  MA Pharmacologic profile of perphenazine's metabolites.  J Clin Psychopharmacol 2000;20181- 187PubMedGoogle ScholarCrossref
87.
Haro  JMEdgell  ETJones  PBAlonso  JGavart  SGregor  KJWright  PKnapp  MSOHO Study Group, The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment.  Acta Psychiatr Scand 2003;107222- 232PubMedGoogle ScholarCrossref
88.
Castner  SAWilliams  GVGoldman-Rakic  PS Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation.  Science 2000;2872020- 2022PubMedGoogle ScholarCrossref
89.
Robbins  TW The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry.  Psychopharmacology (Berl) 2002;163362- 380PubMedGoogle ScholarCrossref
90.
Harvey  PDMoriarty  PJSerper  MRSchnur  ELieber  D Practice-related improvement in information processing with novel antipsychotic treatment.  Schizophr Res 2000;46139- 148PubMedGoogle ScholarCrossref
91.
Harvey  PDRabinowitz  JEerdekens  MDavidson  M Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.  Am J Psychiatry 2005;1621888- 1895PubMedGoogle ScholarCrossref
92.
Fenton  WSBlyler  CRHeinssen  RK Determinants of medication compliance in schizophrenia: empirical and clinical findings.  Schizophr Bull 1997;23637- 651PubMedGoogle ScholarCrossref
93.
Chakos  MHAlvir  JMWoerner  MGKoreen  AGeisler  SMayerhoff  DSobel  SKane  JMBorenstein  MLieberman  JA Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.  Arch Gen Psychiatry 1996;53313- 319PubMedGoogle ScholarCrossref
94.
Lieberman  JAKoreen  ARChakos  MSheitman  BWoerner  MAlvir  JMBilder  R Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.  J Clin Psychiatry 1996;57 ((suppl 9)) 5- 9PubMedGoogle Scholar
Original Article
June 2007

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Author Affiliations

Author Affiliations: Departments of Psychiatry and Behavioral Sciences (Drs Keefe, McEvoy, and Swartz) and Biological Psychiatry, John Umstead Hospital (Dr McEvoy), Duke University Medical Center, Durham, NC; Departments of Psychiatry and Biobehavioral Sciences (Drs Bilder and Green) and Psychology (Dr Bilder), University of California, Los Angeles, Neuropsychiatric Institute; Quintiles Inc, Research Triangle Park, NC (Dr Davis); Department of Psychiatry, Mount Sinai School of Medicine, New York, NY (Dr Harvey); Department of Psychiatry, University of California, San Diego (Dr Palmer); Maryland Psychiatric Research Center, Baltimore (Dr Gold); Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn (Dr Meltzer); Department of Psychiatry, School of Medicine (Drs Capuano, Stroup, and Perkins), and Department of Biostatistics (Dr Davis), University of North Carolina at Chapel Hill; Department of Psychiatry, Yale University School of Medicine, New Haven, Conn (Dr Rosenheck); Adult Psychopharmacology Program, Adult Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, Md (Dr Hsiao); and Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York (Dr Lieberman).

Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.1001/archpsyc.64.6.633
Abstract

Context  Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined.

Objective  To compare the neurocognitive effects of several second-generation antipsychotics and a first-generation antipsychotic, perphenazine.

Design  Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al. Ziprasidone hydrochloride was included after its approval by the Food and Drug Administration.

Setting  Fifty-seven sites participated, including academic sites and treatment mental health facilities representative of the community.

Patients  From a cohort of 1460 patients in the treatment study, 817 completed neurocognitive testing immediately prior to randomization and then after 2 months of treatment.

Main Outcome Measures  The primary outcome was change in a neurocognitive composite score after 2 months of treatment. Secondary outcomes included neurocognitive composite score change at 6 months and 18 months after continued treatment and changes in neurocognitive domains.

Results  At 2 months, treatment resulted in small neurocognitive improvements of z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06), with no significant differences between groups. Results at 6 months were similar. After 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups. Neurocognitive improvement predicted longer time to treatment discontinuation, independently from symptom improvement, in patients treated with quetiapine or ziprasidone.

Conclusions  After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition. There were no differences between any pair of agents, including the typical drug perphenazine. These results differ from the majority of previous studies, and the possible reasons are discussed.

×